Literature DB >> 22896608

Peptide interactions stabilize and restructure human papillomavirus type 16 E6 to interact with p53.

Tina Ansari1, Nicole Brimer, Scott B Vande Pol.   

Abstract

Human papillomavirus type 16 (HPV-16) E6 (16E6) binds the E3 ubiquitin ligase E6AP and p53, thereby targeting degradation of p53 (M. Scheffner, B. A. Werness, J. M. Huibregtse, A. J. Levine, and P. M. Howley, Cell 63:1129-1136, 1990). Here we show that minimal 16E6-binding LXXLL peptides reshape 16E6 to confer p53 interaction and stabilize 16E6 in vivo but that degradation of p53 by 16E6 requires E6AP expression. These experiments establish a general mechanism for how papillomavirus E6 binding to LXXLL peptides reshapes E6 to then act as an adapter molecule.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22896608      PMCID: PMC3457172          DOI: 10.1128/JVI.01236-12

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  27 in total

1.  Cutaneous β-human papillomavirus E6 proteins bind Mastermind-like coactivators and repress Notch signaling.

Authors:  Min Jie Alvin Tan; Elizabeth A White; Mathew E Sowa; J Wade Harper; Jon C Aster; Peter M Howley
Journal:  Proc Natl Acad Sci U S A       Date:  2012-04-30       Impact factor: 11.205

2.  HPV16 E6 confers p53-dependent and p53-independent phenotypes in the epidermis of mice deficient for E6AP.

Authors:  A Shai; M L Nguyen; J Wagstaff; Y-H Jiang; P F Lambert
Journal:  Oncogene       Date:  2006-11-27       Impact factor: 9.867

3.  Solution structure analysis of the HPV16 E6 oncoprotein reveals a self-association mechanism required for E6-mediated degradation of p53.

Authors:  Katia Zanier; Abdellahi ould M'hamed ould Sidi; Charlotte Boulade-Ladame; Vladimir Rybin; Anne Chappelle; Andrew Atkinson; Bruno Kieffer; Gilles Travé
Journal:  Structure       Date:  2012-04-03       Impact factor: 5.006

4.  The stability of the human papillomavirus E6 oncoprotein is E6AP dependent.

Authors:  Vjekoslav Tomaić; David Pim; Lawrence Banks
Journal:  Virology       Date:  2009-08-22       Impact factor: 3.616

5.  Binding of human papillomavirus type 16 E6 to E6AP is not required for activation of hTERT.

Authors:  Pedja Sekaric; Jonathan J Cherry; Elliot J Androphy
Journal:  J Virol       Date:  2007-10-17       Impact factor: 5.103

6.  A single-codon mutation converts HPV16 E6 oncoprotein into a potential tumor suppressor, which induces p53-dependent senescence of HPV-positive HeLa cervical cancer cells.

Authors:  T Ristriani; S Fournane; G Orfanoudakis; G Travé; M Masson
Journal:  Oncogene       Date:  2008-11-17       Impact factor: 9.867

Review 7.  How important are post-translational modifications in p53 for selectivity in target-gene transcription and tumour suppression?

Authors:  A Olsson; C Manzl; A Strasser; A Villunger
Journal:  Cell Death Differ       Date:  2007-07-13       Impact factor: 15.828

8.  HPV E6 degradation of p53 and PDZ containing substrates in an E6AP null background.

Authors:  P Massimi; A Shai; P Lambert; L Banks
Journal:  Oncogene       Date:  2007-10-15       Impact factor: 9.867

9.  Ubiquitin-independent degradation of p53 mediated by high-risk human papillomavirus protein E6.

Authors:  S Camus; S Menéndez; C F Cheok; L F Stevenson; S Laín; D P Lane
Journal:  Oncogene       Date:  2007-01-15       Impact factor: 9.867

10.  Beta-HPV 5 and 8 E6 promote p300 degradation by blocking AKT/p300 association.

Authors:  Heather L Howie; Jennifer I Koop; Joleen Weese; Kristin Robinson; Greg Wipf; Leslie Kim; Denise A Galloway
Journal:  PLoS Pathog       Date:  2011-08-25       Impact factor: 6.823

View more
  23 in total

Review 1.  Papillomavirus E6 oncoproteins.

Authors:  Scott B Vande Pol; Aloysius J Klingelhutz
Journal:  Virology       Date:  2013-05-24       Impact factor: 3.616

2.  HPV-mediated inactivation of tumor suppressor p53.

Authors:  Gilles Travé; Katia Zanier
Journal:  Cell Cycle       Date:  2016-05-31       Impact factor: 4.534

3.  Excessive UBE3A dosage impairs retinoic acid signaling and synaptic plasticity in autism spectrum disorders.

Authors:  Xingxing Xu; Chuanyin Li; Xiaobo Gao; Kun Xia; Hui Guo; Yali Li; Zijian Hao; Lei Zhang; Daming Gao; Chenfan Xu; Huatai Xu; Zhi-Qi Xiong; Zilong Qiu; Ling Mei; Xiaoduo Xie; Kangcheng Ruan; Ronggui Hu
Journal:  Cell Res       Date:  2017-10-27       Impact factor: 25.617

4.  Anti-Condyloma acuminata mechanism of microRNAs-375 modulates HPV in cervical cancer cells via the UBE3A and IGF-1R pathway.

Authors:  Shuying Wu; Hong Chen
Journal:  Oncol Lett       Date:  2018-06-18       Impact factor: 2.967

5.  Deciphering the mechanisms of HPV E6 mutations in the destabilization of E6/E6AP/p53 complex.

Authors:  Le Li; Xuewei Dong; Yiming Tang; Zenghui Lao; Xuhua Li; Jiangtao Lei; Guanghong Wei
Journal:  Biophys J       Date:  2022-03-29       Impact factor: 3.699

Review 6.  Proteomic approaches to the study of papillomavirus-host interactions.

Authors:  Elizabeth A White; Peter M Howley
Journal:  Virology       Date:  2013-01-05       Impact factor: 3.616

7.  Interactions between E6, FAK, and GIT1 at paxillin LD4 are necessary for transformation by bovine papillomavirus 1 E6.

Authors:  Nicole Brimer; Ramon Wade; Scott Vande Pol
Journal:  J Virol       Date:  2014-06-18       Impact factor: 5.103

8.  Human Papillomavirus E6 interaction with cellular PDZ domain proteins modulates YAP nuclear localization.

Authors:  Sydney Webb Strickland; Nicole Brimer; Charles Lyons; Scott B Vande Pol
Journal:  Virology       Date:  2018-01-12       Impact factor: 3.616

Review 9.  PPI Modulators of E6 as Potential Targeted Therapeutics for Cervical Cancer: Progress and Challenges in Targeting E6.

Authors:  Lennox Chitsike; Penelope J Duerksen-Hughes
Journal:  Molecules       Date:  2021-05-18       Impact factor: 4.411

10.  Structural insights into a wildtype domain of the oncoprotein E6 and its interaction with a PDZ domain.

Authors:  André Mischo; Oliver Ohlenschläger; Peter Hortschansky; Ramadurai Ramachandran; Matthias Görlach
Journal:  PLoS One       Date:  2013-04-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.